Pulse Biosciences Appoints Experienced Healthtech CEO Maria Sainz to Board and Audit Committee
Summary
Pulse Biosciences announced the appointment of Maria Sainz, a seasoned healthtech executive with over 30 years of experience, to its Board of Directors and Audit Committee.
Key Events
-
New Director Appointed
Maria Sainz was elected to the Board of Directors, effective January 8, 2026.
-
Audit Committee Role
Ms. Sainz has also been appointed to serve on the Company's Audit Committee.
-
Extensive Healthtech Experience
Ms. Sainz brings over 30 years of operating experience in healthtech, including CEO roles at Hyperfine, AEGEA Medical, CardioKinetix Inc., and Concentric Medical, and leadership positions at Guidant Corporation and Boston Scientific.
-
Public Board Service
She has served on the boards of numerous public companies, including Shockwave Medical, Spectranetics Corp, Avanos Medical, Orthofix Medical Inc, and Hyperfine.
Analysis
The appointment of Maria Sainz significantly strengthens Pulse Biosciences' Board of Directors. Her extensive background, including over 30 years in healthtech with multiple CEO roles and experience on several public medical device company boards, brings critical strategic and operational expertise. This is particularly valuable as Pulse Biosciences advances its nPulse™ technology through clinical, regulatory, and commercial milestones, aligning with her proven track record in guiding companies through growth and commercialization.
At the time of this filing, PLSE was trading at $14.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $997.5M. The 52-week trading range was $12.56 to $25.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.